modelRomidepsin

Diagram of Romidepsin

Extends from Pharmacolibrary.Drugs.ATC.L.L01XH02.

Information

name:Romidepsin
ATC code:L01XH02
route:intravenous
compartments:2
dosage:14mg
volume of distribution:393L
clearance:20.5L/h
other parameters in model implementation

Romidepsin is a cyclic peptide histone deacetylase (HDAC) inhibitor used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). It is approved by regulatory agencies such as the FDA for these indications.

Pharmacokinetics

Pharmacokinetic parameters are reported in adult patients with advanced cancers, administered intravenous infusion over 4 hours. Parameters derived from population PK modeling.

References

  1. Peer, CJ, et al., & Figg, WD (2018). A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer chemotherapy and pharmacology 82(3) 565–570. DOI:10.1007/s00280-018-3631-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29951694

  2. Gerber, DE, et al., & Schiller, JH (2015). Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 90(3) 534–541. DOI:10.1016/j.lungcan.2015.10.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26474959

  3. Stadler, WM, et al., & Thompson, JA (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clinical genitourinary cancer 5(1) 57–60. DOI:10.3816/CGC.2006.n.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16859580

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)